Amyotrophic lateral sclerosis (motor neurone disease)
Development and Regulatory status
May 17: Genervon is planning a PIII trial in 2017 in the US .
Apr 15. Designated orphan drug and fast-track status in US for treatment of ALS. 
Trial or other data
Genervon has completed a phase 2 RCT in ALS (NCTNCT01854294) with 12 participants: this showed clinically and statistically significant benefits over 12 weeks. Further trials are planned. [1, 2] The company allocates a different synonym to the drug depending on indication - GM604 relates to use in ALS.